Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyunsaturated fatty acid 5-lipoxygenase (5-LO or ALOX5) is a non-heme iron-containing dioxygenase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids, primarily arachidonic acid. This leads to the biosynthesis of leukotrienes, which are potent proinflammatory lipid mediators involved in inflammation, immune responses, and various physiological and pathological processes. ALOX5 is the rate-limiting enzyme for leukotriene biosynthesis and is a therapeutic target for conditions like asthma and atherosclerosis. Its activity is regulated by phosphorylation, calcium ions, redox state, and interactions with accessory proteins like FLAP.
Inhibition of leukotriene biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyunsaturated fatty acid 5-lipoxygenase (ALOX5).